Literature DB >> 23715998

Immunization with cytomegalovirus envelope glycoprotein M and glycoprotein N DNA vaccines can provide mice with complete protection against a lethal murine cytomegalovirus challenge.

Huadong Wang1, Yanfeng Yao, Chaoyang Huang, Quanjiao Chen, Jianjun Chen, Ze Chen.   

Abstract

Human cytomegalovirus virions contain three major glycoprotein complexes (gC I, II, III), all of which are required for CMV infectivity. These complexes also represent major antigenic targets for anti-viral immune responses. The gC II complex consists of two glycoproteins, gM and gN. In the current study, DNA vaccines expressing the murine cytomegalovirus (MCMV) homologs of the gM and gN proteins were evaluated for protection against lethal MCMV infection in a mouse model. Humoral and cellular immune responses, spleen viral titers, and mice survival and body-weight changes were examined. The results showed that immunization with gM or gN DNA vaccine alone was not able to offer good protection, whereas co-immunization with both gM and gN induced an effective neutralizing antibody response and cellular immune response, and provided mice with complete protection against a lethal MCMV challenge. This study provides the first in vivo evidence that the gC II (gM-gN) complex may be able to serve as a protective subunit antigen for future HCMV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715998      PMCID: PMC8208358          DOI: 10.1007/s12250-013-3330-9

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  29 in total

Review 1.  Human cytomegalovirus glycoproteins.

Authors:  W J Britt; M Mach
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

2.  The carboxy-terminal domain of glycoprotein N of human cytomegalovirus is required for virion morphogenesis.

Authors:  Michael Mach; Karolina Osinski; Barbara Kropff; Ursula Schloetzer-Schrehardt; Magdalena Krzyzaniak; William Britt
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Cytomegalovirus: pathogen, paradigm, and puzzle.

Authors:  Michael Boeckh; Adam P Geballe
Journal:  J Clin Invest       Date:  2011-05       Impact factor: 14.808

Review 4.  Human cytomegalovirus vaccine: time to look for alternative options.

Authors:  Rajiv Khanna; Don J Diamond
Journal:  Trends Mol Med       Date:  2005-12-07       Impact factor: 11.951

5.  Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects.

Authors:  Michael Mach; Barbara Kropff; Magdalena Kryzaniak; William Britt
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 6.  Viral and host control of cytomegalovirus maturation.

Authors:  Ritesh Tandon; Edward S Mocarski
Journal:  Trends Microbiol       Date:  2012-05-23       Impact factor: 17.079

Review 7.  Update on the current status of cytomegalovirus vaccines.

Authors:  Heungsup Sung; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

8.  Glycoproteins M and N of pseudorabies virus form a disulfide-linked complex.

Authors:  A Jöns; J M Dijkstra; T C Mettenleiter
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Gene transfer into muscle by electroporation in vivo.

Authors:  H Aihara; J Miyazaki
Journal:  Nat Biotechnol       Date:  1998-09       Impact factor: 54.908

10.  The cytoplasmic tail of glycoprotein M (gpUL100) expresses trafficking signals required for human cytomegalovirus assembly and replication.

Authors:  Magdalena Krzyzaniak; Michael Mach; William J Britt
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

View more
  4 in total

1.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

2.  Complete protection of mice against lethal murine cytomegalovirus challenge by immunization with DNA vaccines encoding envelope glycoprotein complex III antigens gH, gL and gO.

Authors:  Huadong Wang; Chaoyang Huang; Jinrong Dong; Yanfeng Yao; Zhenyuan Xie; Xueying Liu; Wenjie Zhang; Fang Fang; Ze Chen
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

3.  Rat Cytomegalovirus Virion-Associated Proteins R131 and R129 Are Necessary for Infection of Macrophages and Dendritic Cells.

Authors:  Iris K A Jones; Nicole N Haese; Philippe Gatault; Zachary J Streblow; Takeshi F Andoh; Michael Denton; Cassilyn E Streblow; Kiley Bonin; Craig N Kreklywich; Jennifer M Burg; Susan L Orloff; Daniel N Streblow
Journal:  Pathogens       Date:  2020-11-19

4.  Antibody Titers Against Human Cytomegalovirus gM/gN and gB Among Pregnant Women and Their Infants.

Authors:  Maria Talavera-Barber; Kaitlyn Flint; Brianna Graber; Ravi Dhital; Irina Kaptsan; Alexandra K Medoro; Pablo J Sánchez; Masako Shimamura
Journal:  Front Pediatr       Date:  2022-06-23       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.